Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cozart clinches UK Home Office deal for confirmation DOA testing:

This article was originally published in Clinica

Executive Summary

Diagnostics developer Cozart has won a contract with the UK Home Office for laboratory oral fluid drug confirmation testing, a deal that could boost the company's top-line by £700,000 ($1.4m) in the first year. The initial one-year, sole-supplier contract is based on a four-year framework agreement between the Abingdon, Oxfordshire-based company and the Home Office. Under the terms of the deal, Cozart will perform follow-up lab confirmation tests - if and when required - for cocaine and heroin after the samples have already been screened (using Cozart's RapiScan test) in police custody suites as part of a national drug interventions programme.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel